( iprazolemetabolism. Agents that induce...)Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia,Health

iprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.

Commonly observed adverse events (greater than or equal to 5% incidence and at a rate at least twice the rate of placebo for aripiprazole vs placebo, respectively):

     Aripiprazole Oral

     In 3-week bipolar mania trials the following were reported: akathisia

     (15% vs 3%), constipation (13% vs 6%), sedation (8% vs 3%), tremor (7% vs

     3%), restlessness (6% vs 3%), and extrapyramidal disorder (5% vs 2%).

     In 4- to 6-week schizophrenia trials the following was reported:

     akathisia (8% vs 4%).

     A similar adverse event profile was observed in a 26-week trial in

     schizophrenia except for a higher incidence of tremor (aripiprazole 8% vs

     placebo 2%).


     Aripiprazole Injection

     In short-term (24 hour) trials in patients with agitation associated with

     schizophrenia or bipolar mania the following was reported: nausea (9% vs

     3%).


    Treatment-emergent adverse events reported with:


     Aripiprazole Oral

     In short-term trials of patients with schizophrenia (up to 6 weeks) or

     bipolar disorder (up to 3 weeks), the following were reported at an

     incidence greater than or equal to 10% and greater than placebo,

     respectively: headache (30% vs 25%), anxiety (20% vs 17%), insomnia (19%

     vs 14%), nausea (16% vs 12%), vomiting (12% vs 6%), dizziness (11% vs

     8%), constipation (11% vs 7%), dyspepsia (10% vs 8%), and akathisia (10%

     vs 4%).


     Aripiprazole Injection

     In short-term (24 hour) trials, the following were reported at an

     incidence greater than or equal to 5% and greater than placebo,

     respectively: headache (12% vs 7%), nausea (9% vs 3%), dizz
'"/>




Page: 1 2 3 4 5 6 7 8 9 
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial
Combination Therapy with Januvia (sitagliptin) and Metformin Led to
Improvement in Markers of Beta Cell Function in Patients with Type
2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational
Use of Januvia and Metformin as Initial Combination Therapy
Provided Significant Glucose Lowering Efficacy over 54 Weeks in
Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical
Improvement with Orencia (Abatacept) in Children with Juvenile
Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational
Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients
With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in
Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine
Extended Release, An Investigational Nonstimulant Medication Filed
for the Treatment of ADHD in Children and Adolescents